Abstract Bullous pemphigoid (BP) is the most frequent autoimmune bullous skin disease, characterised by autoantibodies against the hemidesmosome complex. Recently, regulatory T cells (Tregs) have been implicated in the development of several autoimmune diseases; few data are available in BP, failing to demonstrate a role of this subset in disease pathogenesis. The aim of this study was to investigate the expression and phenotypes of different Tregs (CD4? CD25brightFOXP3? and CD8? CD28-cells) in BP to clarify whether the depletion of this subset constitutes one mechanism of tolerance loss. The CD4? CD25brightFOXP3 and CD8? CD28-circulating subsets were determined by flow-cytometry in 26 untreated BP patients and compared with a group of age-and sex-matched healthy controls (HC, n = 30). Absolute and percentage values of the CD4? CD25brightFOXP3? cells were significantly reduced in BP compared with HC (median CD25brightFOXP3? expression within CD4? cells: 1.8 vs. 3.5%, p = 0.002); conversely, BP patients were characterised by a significant expansion of the CD25brightFOXP3-''activated'' T-cell subset. CCR4 and CD62L were expressed on the majority of CD4? CD25brightFOXP3? cells (75.2 and 82.3%, respectively). No differences in the CD8? CD28-subset were found between BP and HC. This is the first report showing a significant reduction of circulating CD4? CD25bright-FOXP3? Treg frequency in BP patients.
Introduction
Bullous pemphigoid (BP), the most common autoimmune blistering disease, is characterised by presence of autoantibodies directed against components of the hemidesmosome adhesion complex, the BP230 and collagen XVII/ BP180 proteins. The pathogenesis of disease involves also development of BP180-specific auto-reactive T cells, accumulation of other inflammatory cells, complement activation, mast-cell degranulation and protease release [6, 8, 11, 38] .
Numerous immune-mediated diseases have been shown to present a reduction and/or function impairment of regulatory T cells (Tregs) [21, 28] , a subset of effector cells which play an important role in tolerance control by silencing self-reactive T cells. In previous studies, we found a significant Treg down-modulation in immunemediated skin diseases (psoriasis, scleroderma, dermatomyositis, lupus and Graft-versus-Host-Disease (GvHD) [1-3, 25, 26] . Distinct Treg subsets have been described [10, 19] . The bright CD25 expression identifies both naturally occurring Tregs (nTregs), characterized by the intracellular expression of transcription factor forkhead-box-P3 (FOXP3) and ''antigen induced'' Tregs, whose suppressive functions are mediated by IL-10 and TGF-b release. CD8? suppressor lymphocytes are CD28negative, do not determine apoptosis and induce immune suppression through an antigen-or non-antigen-specific mechanism [5, 9, 13, 14] .
To date few studies focused on Tregs in autoimmune bullous skin diseases. A significant depletion of Tregs was demonstrated in pemphigus vulgaris (PV) [31, 35] . Experimental studies confirmed that FoxP3 inhibition abrogated the suppressor activity on desmoglein3-specific cell clones [36, 37] and that anti-desmoglein-3 auto-antibodies were suppressed by the adoptive transfer of Tregs [39] . As for BP, only two papers were published, reporting conflicting results [4, 27] . One study [27] failed to demonstrate significant differences in Treg number in both skin and blood of 14 BP patients with respect to healthy donors, Tregs from BP patients maintaining also their ability to suppress T-cell proliferation [27] . A recent paper [4] showed, however, a significant lower expression of FOXP3? Treg cells in the lesional skin of BP compared with PV patients, coupled with an accumulation of Th17 cells.
The aim of this study was to investigate the expression and phenotypes of two distinct Treg circulating subsets (CD4? CD25brightFOXP3? and CD8? CD28-) in BP patients to clarify whether the depletion of this subset constitutes one potential mechanism of tolerance loss induction.
Materials and methods

Patients
Twenty-six BP patients (17 males, 9 females; median age 74 years, range: 59-88) were enrolled, after getting their written informed consent, in two Italian dermatological centres (Florence and Turin). The study was approved by the Ethics Committee in each institution. All the patients were included at the time of first BP diagnosis before receiving steroids or other immuno-suppressive therapies.
BP diagnosis was based on the following criteria: typical clinical features, with skin blistering in elderly patients; subepidermal blistering and eosinophil/neutrophil inflammatory infiltrate; linear IgG/C3 deposits along the dermalepidermal junction at direct immunofluorescence examination, linear IgG deposits at the blister roof of sodium chloride split human skin at indirect immunofluorescence; circulating anti-BPAg2 (collagen XVII/BP180) antibodies at enzyme-linked immunosorbent assay (ELISA). Disease extent and severity was graded according to the ABSIS score (autoimmune bullous skin disorder intensity score) [24] (scoring range 0-206, 150 points maximum for skin involvement, 11 for oral involvement and 45 for subjective discomfort).
Flow cytometric analysis
Peripheral blood sampling was performed during the first visit before systemic treatment was started. A group of ageand sex-matched healthy subjects (n = 30) were used as healthy controls (HC). Peripheral blood lymphocyte samples were evaluated according to their immunofluorescence reactivity using FACSCalibur/FACSCanto TM II cytometers and analyzed with CellQuest/FACSDiva (Becton-Dickinson, San Josè, CA, USA). Surface markers were performed by four-or six-colour immunofluorescence analyses, using simultaneously antibodies conjugated to FITC, PE, PerCP or PerCP Cy5.5, Pe-Cy7, APC and APC-H7. At least 10,000 lymphocytes were collected for each antibody combination. Lymphocyte purity was verified by standard forward and sideways scattering parameters, using a CD45 gating analysis. The following MoAbs were analysed: CD3 FITC, PerCP Cy5.5 or APC-H7 (SK7, mouse IgG1), CD4 PerCP or Pe-Cy7 (SK3, mouse IgG1) CD8 APC-H7 (SK1, mouse IgG1), CD16 FITC (NKP15, mouse IgG1), CD19 APC (SJ25C1, mouse IgG1), CD28 PE (CD28.2, IgG1), CD56 PE (MY31, IgG1), anti-CCR4 PE (IG1, IgG1), anti CD25 PE or APC (M-A251, mouse IgG1), anti CD62L PE or APC (Dreg 56, mouse IgG1), all purchased from BD Biosciences (San Diego, CA, USA).
The CD4? CD25? population can be divided into two different levels of expression, i.e. low CD25 level (defined CD4? CD25low) and high CD25 level (defined CD4? CD25bright) [9] [10] [11] [12] [13] that appear to have a tail to the right of the major population containing both CD4? CD25low and CD4? CD25-cells. FOXP3 expression was analysed using mononuclear cells purified from peripheral blood using Lymphoprep (1.077 g mL; Axis-Shield, Oslo, Norway) density gradient centrifugation. The cells were incubated with surface antibodies, anti-CD4 PerCP or PE-Cy7 and anti-CD25 APC for 10 min at room temperature, then stained with anti-FOXP3 PE (clone PCH101, rat IgG2a; eBiosciences, San Diego, CA, USA), according to the manufacturer's protocol, using fixation and permeabilisation buffers from the same provider. nTreg values were determined as the percentage of CD25brightFOXP3? within the CD3? CD4? compartment.
Statistical analysis
The results are presented as medians, 25th-and 75th-percentile. The Mann-Whitney U test and the Kruskal-Wallis with Dunn posthoc test were used to compare data, giving similar results. p \ 0.05 was considered statistically significant.
Results
Circulating T-cell subsets
No significant differences in the median percentage values of circulating T CD3? CD4? and CD3? CD8?, B and natural killer (NK) cells were found between BP patients and HC (Table 1) .
By contrast, CD25brightFOXP3? expression within the CD4? subset was significantly lower in BP patients (median: 1.8%, 25th-75th percentile: 1-3.1%) than in HC (median: 3.5%, 25th-75th percentile: 3-4%) (p = 0.002) (Fig. 1a) . (Fig. 1b) (Fig. 2) . This implies that BP patients are characterised by a significant expansion of the CD25brightFOXP3-''activated'' T-cell subset with respect to HC. CCR4 and CD62L were expressed on the majority of CD4? CD25brightFOXP3? cells (median: 75.2 and 82.3%, respectively).
Discussion
Our study shows for the first time that BP patients are characterised by a significant reduction in the percentage and absolute values of circulating CD4? CD25bright-FOXP3? Tregs, associated with an opposite up-regulation of the CD4? CD25bright ''inflammatory'' cell subset. On the other hand, we failed to demonstrate a significant modification in CD8? CD28-Treg cells [22, 34] . However, this latter subset has been found reduced in immunedriven diseases such as type-1 juvenile diabetes mellitus and systemic lupus erythematosus affecting predominantly young people [22, 34] ; the age of the patients can play a role in this phenomenon as it is known that the CD8? CD28-subset increases with age [12, 30] and BP affects predominantly elderly people (74 years median age in this study).
The CD25bright expression does not exclusively identifies this T-cell population as it can be found also on activated T cells and APC [10, 19] , whilst FOXP3 is the most exclusive Treg marker as the inhibitory properties lies in the FOXP3? subset [10, 18, 20, 32, 33] . Indeed, BP patients were characterised by a significant expansion of the CD4? CD25bright and reduction of the CD4? CD25-subset with respect to HC, which was coupled by an opposite marked down-regulation of the FOXP3? compartment (64.3% of the CD4? CD25bright subset were FOXP3 negative). From a biological point of view, these data suggest that in BP patients, the Treg reduction is Table 2 Phenotype characterisation of circulating subsets on the basis of CD25 expression intensity associated with an expansion of the ''activated'' CD25brightFOXP3-inflammatory compartment. These findings can at least partially explain the discrepancies between our study and that of Rensing-Ehl et al. [27] . In that paper, circulating Tregs were analysed on the basis of the CD25bright expression; even if FOXP3 expression was reported to be higher among the CD4? CD25bright subset, no specific comparison data as to FOXP3 expression in BP and HC are shown. The paper by Rensing-Ehl et al. [27] reports two other main findings which are not available in our study, the presence of significant amounts of FOXP3? cells in the lesional BP skin and the absence of functional Treg impairment. Indeed, patients with rheumatoid arthritis demonstrated a significant Treg increase in synovial fluid suggesting that recruitment to inflammatory sites may be responsible for circulating Treg reduction [23] . This phenomenon has not been demonstrated in BP, as the recent data by Arakawa et al. [4] showed a significant reduction in FOXP3? cells in BP lesional skin compared with pemphigus vulgaris. As to the effective functional properties of these cells, the phenotypic characterisation performed in our study can give some more insights. Our data showed that the large majority (70-80%) of CD4? CD25? bright cells expressed CCR4 and CD62L. CCR4 is a chemokine receptor involved in the recruitment of skin-specific lymphocytes [7] . Hirahara et al. [16] showed that virtually all circulating CD4? CD25brightFOXP3? Treg expressed high CCR4 levels, and that this subset showed marked suppressive properties. CCR4 expression may drive Treg cells to sites of antigen presentation (such as the skin in BP patients) supporting the down-regulation of T-cell activation [17] . As to CD62L expression, CD4? CD25bright nTregs positive for L-selectin display a significantly stronger suppressor activity than the negative ones [15, 29] . Taken together, the CD4? CD25brightFOXP3? cells shown to be reduced in BP patients exhibited the Tregs characteristic phenotypic features. The Treg phenotypic modulation shown by our study in BP patients is similar to that reported in PV patients where a reduction in circulating Tregs and a preferential CCR4 and CD62L expression on the CD4? CD25bright cells were reported [31] .
In conclusion, this study shows for the first time a significant down-regulation of circulating Tregs in BP patients. Future studies are mandatory to identify the effective role of this modification in the disease pathogenesis as well as its relationship with the clinical response. Fig. 2 Representative dot plots from a BP patient (Fig. 2a) and a normal control (HC, Fig. 2b) showing the reduction of the FOXP3? cells within the CD25 bright subset Arch Dermatol Res (2012) 304:639-645 643
